© 2001 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Serum C3 but Not Plasma Acylation-Stimulating Protein Is Elevated in Finnish Patients With Familial Combined Hyperlipidemia
From the Department of Medicine, Helsinki University Central Hospital (K.Y., N.M.-M., J.V., M.-R.T.), and Department of Bacteriology and Immunology, the Haartman Institute (S.M.), University of Helsinki, and the Department of Medicine, Turku University Central Hospital, University of Turku, (I.N.), Finland; and the Department of Human Genetics, the Gonda (Goldschmied) Neuroscience and Genetics Research Center (P.P., R.M.C., I.N.), and Department of Pediatrics (R.M.C.), UCLA, Los Angeles, Calif.
Correspondence to Dr Marja-Riitta Taskinen, Department of Medicine, PO Box 340, Floor 11, Haartmaninkatu 4, 00029 Huch, Finland. E-mail marja-riitta.taskinen{at}hus.fi
Abstract—A trapping defect of fatty acids due to impaired function of acylation-stimulating protein (ASP) has been suggested as one mechanism underlying the metabolic abnormalities in familial combined hyperlipidemia (FCHL). The study aimed at defining the role of ASP and complement C3 in 35 Finnish FCHL families. There was no difference in plasma ASP levels between the 66 hypertriglyceridemic FCHL patients and their 84 normotriglyceridemic relatives. No response in plasma ASP could be observed after a fatty meal in 10 FCHL patients or in 10 control subjects. In familial correlation analyses, C3 exhibited a significant sibling-sibling correlation. The FCHL patients had higher serum C3 levels than their unaffected relatives (P<0.001). Furthermore, serum C3 levels correlated significantly with several lipid parameters. The correlations between ASP and lipid variables were weaker than those of C3. These analyses suggest that common genes might contribute to the regulation of serum C3, triglycerides, HDL-C, free fatty acids, and insulin. The present data do not support the hypothesis that defects of the ASP pathway are reflected in plasma lipoproteins or in impaired plasma lipid clearance postprandially.
Key Words: acylation-stimulating protein • complement • familial hyperlipidemia • postprandial • atherosclerosis
This article has been cited by other articles:
 |
|
 |
|
  J. Li, P. C. Pircher, I. G. Schulman, and S. K. Westin Regulation of Complement C3 Expression by the Bile Acid Receptor FXR J. Biol. Chem., March 4, 2005; 280(9): 7427 - 7434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Tsutsui, F. Xie, M. Cano, J. Chomas, P. Phillips, S. J. Radio, J. Lof, and T. R. Porter Detection of retained microbubbles in carotid arteries with real-time low mechanical index imaging in the setting of endothelial dysfunction J. Am. Coll. Cardiol., September 1, 2004; 44(5): 1036 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J van Oostrom, H. van Dijk, C. Verseyden, A. D Sniderman, K. Cianflone, T. J Rabelink, and M. Castro Cabezas Addition of glucose to an oral fat load reduces postprandial free fatty acids and prevents the postprandial increase in complement component 3 Am. J. Clinical Nutrition, March 1, 2004; 79(3): 510 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Verseyden, S. Meijssen, H. van Dijk, H. Jansen, and M. C. Cabezas Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia J. Lipid Res., November 1, 2003; 44(11): 2100 - 2108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Meijssen, H. van Dijk, C. Verseyden, D.W. Erkelens, and M. C. Cabezas Delayed and Exaggerated Postprandial Complement Component 3 Response in Familial Combined Hyperlipidemia Arterioscler. Thromb. Vasc. Biol., May 1, 2002; 22(5): 811 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ozata, C. Oktenli, M. Gulec, T. Ozgurtas, F. Bulucu, K. Caglar, N. Bingol, A. Vural, and I. C. Ozdemir Increased Fasting Plasma Acylation-Stimulating Protein Concentrations in Nephrotic Syndrome J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 853 - 858. [Abstract] [Full Text] [PDF]
|
|